• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Vera Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

    6/3/25 6:36:50 AM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VERA alert in real time by email
    8-K
    false 0001831828 0001831828 2025-06-02 2025-06-02
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): June 2, 2025

     

     

    Vera Therapeutics, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-40407   81-2744449

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    2000 Sierra Point Parkway, Suite 1200  
    Brisbane, California   94005
    (Address of principal executive offices)   (Zip Code)

    (650) 770-0077

    Registrant’s telephone number, including area code

    Not Applicable

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange

    on which registered

    Class A common stock, $0.001 par value per share   VERA   The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 1.01

    Entry into a Material Definitive Agreement.

    On June 2, 2025 (the “Effective Date”), Vera Therapeutics, Inc. (the “Company”) entered into a Loan and Security Agreement (the “Agreement”) with Oxford Finance LLC, as collateral agent (in such capacity, the “Collateral Agent”), and certain lenders from time to time party thereto (collectively, the “Lenders”). The Agreement provides for term loans in an aggregate principal amount of up to $500.0 million.

    Under the terms of the Agreement, the Lenders have agreed to make term loans to the Company in multiple tranches, subject to certain conditions. The initial tranche of $125.0 million will be fully available on June 4, 2025, of which $75.0 million will be funded on such date and the remaining $50.0 million may be drawn during 2026, with three additional tranches in an aggregate principal amount of up to $175.0 million available upon the achievement of specified milestones and conditions and one additional uncommitted tranche in an aggregate principal amount of up to $200.0 million available upon the mutual agreement of the Company and the Lenders.

    The term loans bear interest at a floating per annum rate equal to the greater of (x) the 1-Month CME Term SOFR plus 4.95% and (y) 8.70%. The term loans mature on June 1, 2030, or June 1, 2031, depending on the achievement of certain milestones. The Company is required to make monthly payments of interest only until August 1, 2029 (if the maturity date is June 1, 2030), or until August 1, 2030 (if the maturity date is June 1, 2031), after which monthly payments of principal and interest will be due.

    The Agreement includes customary representations, warranties, and covenants, including financial covenants requiring the Company to maintain certain liquidity levels or loan coverage ratios, as applicable. The Agreement also includes events of default, which, if triggered, could result in the acceleration of the Company’s repayment obligations.

    The Company granted the Collateral Agent a security interest in substantially all of its assets, excluding, as of the Effective Date, intellectual property, to secure its obligations under the Agreement.


    The foregoing description of the Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

     

    Item 2.03

    Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

    The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.

     

    Item 9.01

    Financial Statements and Exhibits.

    (d) Exhibits.

     

    Exhibit

    No.

      

    Description

    10.1¥    Loan and Security Agreement between Vera Therapeutics, Inc. and Oxford Finance LLC, as collateral agent, and certain lenders including Oxford Finance Credit Fund II LP, Oxford Finance Credit Fund III LP, and Oxford Finance Credit Fund IV LP and the other parties thereto, dated June 2, 2025.
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

    ¥

    Certain of the exhibits and schedules to this exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5). The Company agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request.


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

          Vera Therapeutics, Inc.
    Date: June 3, 2025     By:  

    /s/ Marshall Fordyce, M.D.

         

    Marshall Fordyce, M.D.

    Chief Executive Officer

    Get the next $VERA alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $VERA

    DatePrice TargetRatingAnalyst
    5/5/2025$75.00Buy
    H.C. Wainwright
    2/4/2025$49.00Outperform
    Wolfe Research
    1/28/2025$58.00Buy
    Goldman
    11/21/2024$70.00Overweight
    Wells Fargo
    10/16/2024Sector Outperform
    Scotiabank
    1/25/2024$26.00Outperform
    Oppenheimer
    1/8/2024Overweight
    Cantor Fitzgerald
    12/18/2023$29.00Outperform
    Raymond James
    More analyst ratings

    $VERA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      BRISBANE, Calif. , July 10, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that on July 6, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 133,500 shares of Class A common stock and restricted stock units (RSUs) for 73,695 shares of Class A common stock to fifteen (15) new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option granted on July 6, 2025 has an exercise price per share equal to $24.00, Vera's closing trading price on July 3, 2

      7/10/25 7:05:19 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      BRISBANE, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that on June 3, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 124,000 shares of Class A common stock and restricted stock units (RSUs) for 65,925 shares of Class A common stock to seventeen (17) new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option granted on June 3, 2025 has an exercise price per share equal to $30.91, Vera's closing trading price on June 3,

      6/9/25 4:05:00 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

      BRISBANE, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference, which is taking place in Miami Beach, FL from June 9 – 11, 2025. The management team will also participate in one-on-one investor meetings. Fireside Chat Details:Date: Wednesday, June 11, 2025 Time: 3:15pm EDTWebcast: https://cc.webcasts.com/gold006/060925a_js/?entity=165_UH4O74B A replay of

      6/4/25 4:05:00 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright resumed coverage on Vera Therapeutics with a new price target

      H.C. Wainwright resumed coverage of Vera Therapeutics with a rating of Buy and set a new price target of $75.00

      5/5/25 9:37:24 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wolfe Research initiated coverage on Vera Therapeutics with a new price target

      Wolfe Research initiated coverage of Vera Therapeutics with a rating of Outperform and set a new price target of $49.00

      2/4/25 7:12:11 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Goldman initiated coverage on Vera Therapeutics with a new price target

      Goldman initiated coverage of Vera Therapeutics with a rating of Buy and set a new price target of $58.00

      1/28/25 8:54:12 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERA
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Vera Therapeutics Inc.

      SCHEDULE 13G - Vera Therapeutics, Inc. (0001831828) (Subject)

      6/11/25 5:38:07 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vera Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

      8-K - Vera Therapeutics, Inc. (0001831828) (Filer)

      6/3/25 6:36:50 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vera Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Vera Therapeutics, Inc. (0001831828) (Filer)

      6/2/25 6:36:56 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Enright Patrick G bought $5,277,311 worth of shares (250,000 units at $21.11) (SEC Form 4)

      4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

      6/25/25 8:07:16 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Katabi Maha

      4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

      5/16/25 4:13:51 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Enright Patrick G

      4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

      5/16/25 4:13:01 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Enright Patrick G bought $5,277,311 worth of shares (250,000 units at $21.11) (SEC Form 4)

      4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

      6/25/25 8:07:16 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Katabi Maha bought $4,999,990 worth of shares (161,290 units at $31.00) (SEC Form 4)

      4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

      2/1/24 5:58:54 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Vera Therapeutics Inc.

      SC 13G/A - Vera Therapeutics, Inc. (0001831828) (Subject)

      11/14/24 4:10:28 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Vera Therapeutics Inc.

      SC 13G/A - Vera Therapeutics, Inc. (0001831828) (Subject)

      11/14/24 4:05:17 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Vera Therapeutics Inc.

      SC 13G - Vera Therapeutics, Inc. (0001831828) (Subject)

      11/14/24 1:22:39 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERA
    Leadership Updates

    Live Leadership Updates

    See more
    • Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer

      BRISBANE, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Jason S. Carter as Chief Legal Officer, effective immediately. "We are excited to have Jason join our growing team. With our pivotal ORIGIN 3 trial of atacicept in IgAN on track to announce topline results in the second quarter of 2025 and planned BLA submission to the FDA anticipated later in the year, pending data, we are actively building out our team with experienced professionals who will help us succ

      11/18/24 8:00:00 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Officer

      BRISBANE, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of David L. Johnson as Chief Operating Officer, effective immediately. "We are excited to have David join our executive team at this important time for our clinical program of atacicept for the treatment of IgAN. We expect long-term 96-week data from the Phase 2b ORIGIN trial later this year and primary endpoint results from our pivotal Phase 3 clinical trial in the first half of 2025, and we look forward to

      7/1/24 8:00:00 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vera Therapeutics Appoints Christy J. Oliger to Board of Directors

      BRISBANE, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Christy J. Oliger to its board of directors, effective June 7, 2024. Ms. Oliger brings over 30 years of experience in the biopharmaceutical industry, including being recognized for building highly effective teams and leading significant commercial product launches. "We are delighted to welcome Christy to our Board during this important period in Vera's history. Her extensive experience and counsel will be

      6/11/24 4:01:00 PM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERA
    Financials

    Live finance-specific insights

    See more
    • Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy

      Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared to placebo at week 36 (p<0.0001)Other prespecified endpoints achieved similar or better results compared to the ORIGIN Phase 2b clinical trial — per FDA guidance, Vera is not sharing eGFR results at this time while the ORIGIN 3 placebo-controlled trial continuesThe safety profile of atacicept was favorable, and comparable to placebo Vera plans to meet with FDA in the coming weeks to discuss these results and the regulatory pathway; Vera currently plans to submit a Biologics License Application

      6/2/25 6:30:00 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor

      BRISBANE, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B cell mediated diseases. "This novel approach is part of Vera's broad lifecycle management strategy to expand and extend our leadership position within B cell modulation, which we believe has the potential to transform how we tre

      1/13/25 7:00:00 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vera Therapeutics Announces Positive Week 36 Efficacy and Safety Results of Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN in Late-Breaking Presentation at 60th European Renal Association (ERA) Congress

      New data at week 36 shows atacicept 150 mg resulted in a delta of 43% versus placebo in mean proteinuria reduction in per-protocol analysis and demonstrated statistically significant stabilization of eGFR versus placebo in this high-risk population Atacicept was well tolerated with safety profile similar to placebo Positive results support atacicept 150 mg as a potential disease-modifying treatment for patients with IgA nephropathy; Phase 3 (ORIGIN 3) clinical trial initiated in June 2023 Conference call and webcast to take place on June 20th, 2023, at 8:00 a.m. ET to further discuss results BRISBANE, Calif., June 17, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a la

      6/17/23 10:10:00 AM ET
      $VERA
      Biotechnology: Pharmaceutical Preparations
      Health Care